| Latest News & Updates... | ||
|---|---|---|
|
||
| A Friendly Skeptic Looks at Goji |
|
|
| Sunday, 21 November 2004 | |||
|
Effects on Cancer
|
|||
![]() |
Pictured Above: A drawing of goji, from Prof. Dr. OttoWilhelm Thomé's Flora von Deutschland Österreich und der Schweiz Click image for a larger view |
The Evidence
There is plenty of charming folklore surrounding the goji berry. But the real question is whether there is compelling enough evidence to justify spending $44 for a bottle of fruit juice.
PubMed, the US government's comprehensive database of 15 million medical journal citations, lists a total of 102 articles on Lycium species. Fifty of these are on Lycium barbarum. Most of these concern laboratory tests, and only five articles even mention cancer. If we restrict our consideration to just clinical trials (structured studies involving human subjects) there are precisely two. One is irrelevant to our purposes, since it does not concern cancer (Breithaupt 2004).
A Single Report
This leaves a single report of a clinical trial in cancer using a goji extract. It was carried out by G.W. Cao and colleagues at the Second Military Medical University in Shanghai and published in a Chinese medical publication, the Chinese Journal of Oncology. Seventy-nine patients with advanced cancer were enrolled in a trial in which they were treated with lymphocyte-activated killer (LAK) cells + interleukin-2 (IL-2). But some of the patients also received polysaccharides (complex sugars) derived from Lycium barbarum (abbreviated LBP).
Initial results of the treatment from 75 evaluable patients indicated that "objective regression of cancer was achieved in patients with malignant melanoma, renal cell carcinoma, colorectal carcinoma, lung cancer, nasopharyngeal carcinoma." It also was supposedly effective in "malignant hydrothorax" (which presumably refers to pleural effusion, a collection of fluid within the chest cavity which frequently accompanies thoracic cancers).
According to this Chinese article, the response rate of patients treated with LAK + IL-2 alone was 16.1 percent. But when goji extract was given to some patients the response rate jumped to 40.9 percent. The authors also state that the remission in patients treated with LAK + IL-2 plus goji extract lasted significantly longer and led to a more marked increase in natural killer (NK) cell activity than LAK + IL-2 alone.
"The results indicate that LBP can be used as an adjuvant in the biotherapy [i.e., immunotherapy] of cancer," the authors concluded.
This is a potentially important finding. A juice that can double the response rate to standard cancer treatment would be worth many multiples of $44. However, there remain numerous questions about this clinical trial that might be difficult to answer, since all there is to go on is an abstract in PubMed. The full article is in a Chinese journal that does not maintain an English-language website. Dr. Gao is the co-author of just seven PubMed articles, none of which gives his contact information.
If, however, I could interview Dr. Gao here are some of the questions I would ask:
How many patients were treated in each group?
What exactly is your standard for an "objective regression"?
How much longer did the remissions last in the goji-added group than the control group?
Was there any effect on disease-free or overall survival?
Have there been any follow-up studies using goji with drugs in a single form of the disease?
Additionally, this Chinese study uses a non-standard therapy for many of these cases, i.e. LAK + IL-2. This was a "hot" therapy in the 1980s and early 1990s, primarily because of the advocacy of Steven Rosenberg, MD, of the National Cancer Institute (Rosenberg 1993). But is rarely used today. Indeed, the NCI has stated that the addition of LAK to IL-2 has "not improved response rates or durable remissions sufficiently to merit the expense and complexity of this therapy" (NCI 2004). Even the NCI's clinical trials database (www.clinicaltrials.gov) does not list a current clinical trial using these once popular treatments (Kimura 1997). So this small goji trial uses an outdated therapy. It would, however, be interesting to see what goji extract could do when added to the current treatment for a group of patients with biopsy-confirmed cancer of a single type.
Therefore, although I am intrigued by Dr. Gao's findings, I would still recommend that patients hold onto their $44 until there is better documentation of the drink's purported effects. By comparison to goji, something as simple as green tea looks to have an equal or even better effect at about one-hundredth of the cost. Over 1,000 articles on tea and cancer have already been published in the medical literature, of which 19 refer to randomized, controlled trials. A study published in February, 2004 showed that when heavy smokers drank four cups of green tea per day for four months there was a significant decrease in a urinary marker of DNA damage (Hakim 2004). Green tea might also be beneficial for those undergoing conventional treatment for cancer, although that is far from proven.
The network marketeers are hoping we will go chasing after goji, in mankind's never ending quest for a magic potion to cure our most persistent ills. However, we would be far better off to let science be our guide. There are more effective, better proven, and certainly less expensive alternatives available to all.
Caution: Every indication is that goji is safe to drink in moderation. However, there is one exception to that rule. Like some other natural products, it may have anti-coagulant activity. While this is generally desirable, it could lead to a dangerous situation for anyone who is taking the prescription medication Warfarin (coumadin). One should therefore be careful about taking the two together, as this could lead to dangerous episodes of bleeding (Lam 2001).
--Ralph W. Moss, Ph.D.
References:
Breithaupt DE, Weller P, Wolters M, Hahn A. Comparison of plasma responses in human subjects after the ingestion of 3R,3R'-zeaxanthin dipalmitate from wolfberry (Lycium barbarum) and non-esterified 3R,3R'-zeaxanthin using chiral high-performance liquid chromatography. Br J Nutr. 2004;91:707-13.
Cao GW, Yang WG, Du P. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients] Zhonghua Zhong Liu Za Zhi. 1994;16:428-31.
Dafni A,.Yaniv Z. Solanaceae as medicinal plants in Israel. J Ethnopharmacol. 1994;44:11-8.
Gan L, Wang J, Zhang S. [Inhibition the growth of human leukemia cells by Lycium barbarum polysaccharide]. Wei Sheng Yan Jiu. 2001;30:333-5.
Gan L, Zhang SH, Liu Q, Xu HB. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. Eur J Pharmacol. 2003;471:217-22.
Hakim IA, Harris RB, Chow HH, Dean M, Brown S, Ali IU. Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: role of glutathione S-transferase genotypes. Cancer Epidemiol Biomarkers Prev. 2004;13:242-9.
Huang Y, Tan A, Shen Y, Lu J. [Scavenging effect of total flavonoids of lycium barbarum L on active oxygen radicals and inhibitory effects on heat output from L1210 cells] Wei Sheng Yan Jiu. 1998;27:109-11, 115.
Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 1997;80:42-9.
Lam AY, Elmer GW, Mohutsky MA. Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother. 2001;35:1199-201.
Liu XL, Sun JY, Li HY, Zhang L, Qian BC. [Extraction and isolation of active component for inhibiting PC3 cell proliferation in vitro from the fruit of Lycium barbarum L.] Zhongguo Zhong Yao Za Zhi. 2000;25:481-3.
Lu CX, Cheng BQ. [Radiosensitizing effects of Lycium barbarum polysaccharide for Lewis lung cancer] Zhong Xi Yi Jie He Za Zhi. 1991;11:611-2, 582.
Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993 ;85:622-32.
| < Prev | Next > |
|---|
|
| Moss Reports Audio Clips |
|---|
|
| Cancer Decisions Podcasts |
|---|
|
|
| Syndicate |
|---|







